Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Chiara Crotti, Martina Biggioggero, Andrea Becciolini, Elena Agape & Ennio Giulio Favalli. (2019) Mavrilimumab: a unique insight and update on the current status in the treatment
of rheumatoid arthritis. Expert Opinion on Investigational Drugs 28:7, pages 573-581.
Read now
Read now
Chiara Crotti, Maria Gabriella Raimondo, Andrea Becciolini, Martina Biggioggero & Ennio Giulio Favalli. (2017) Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Design, Development and Therapy 11, pages 211-223.
Read now
Read now
Kathryn L. Pothoven & Robert P. Schleimer. (2017) The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease. Tissue Barriers 5:3.
Read now
Read now
Xiujuan Wu, Juan Wang, Kangding Liu, Jie Zhu & Hong-Liang Zhang. (2016) Are Th17 cells and their cytokines a therapeutic target in Guillain–Barré syndrome?. Expert Opinion on Therapeutic Targets 20:2, pages 209-222.
Read now
Read now
Samra Sardar & Åsa Andersson. (2016) Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development. Immunopharmacology and Immunotoxicology 38:1, pages 2-13.
Read now
Read now
Mahdi Alahgholi-Hajibehzad, Pinar Kasapoglu, Reza Jafari & Nima Rezaei. (2015) The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics. Expert Review of Clinical Immunology 11:7, pages 859-870.
Read now
Read now
Articles from other publishers (28)
Deming Jiang. 2023. Joint and Bone. Joint and Bone
141
168
.
Theodora Kalpachidou, Lydia Riehl, Clemens L. Schöpf, Buket Ucar & Michaela Kress. (2022) Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain. Pain 163:S1, pages S79-S98.
Crossref
Crossref
Pritha Shah, Aqsa Siddique, Ami Thakkar, Sankalp Gharat, Angel Godad, Pravin Kale & Gaurav Doshi. (2022) An update on novel therapeutic intervention in Rheumatoid arthritis. International Immunopharmacology 109, pages 108794.
Crossref
Crossref
Jianan Zhao, Shicheng Guo, Steven J. Schrodi & Dongyi He. (2021) Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications. Frontiers in Immunology 12.
Crossref
Crossref
Chao-Yi Wu, Huang-Yu Yang, Jing-Long Huang & Jenn-Haung Lai. (2021) Signals and Mechanisms Regulating Monocyte and Macrophage Activation in the Pathogenesis of Juvenile Idiopathic Arthritis. International Journal of Molecular Sciences 22:15, pages 7960.
Crossref
Crossref
Laila Salah Shamseldin, Mohamed Mohamed Shawqi, Noor Adel Al Hashem, Majd Aleslam Hussein Alhyari, Hossam Aldein Samir Abd Elazeem, Shrouk M. Elghazaly, Aboalmagd Hamdallah, Khaled Mohamed Ragab & Anas Zakarya Nourelden. (2021) Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Current Rheumatology Reviews 17:2, pages 184-192.
Crossref
Crossref
Kinal Bhatt, Radhika Garimella, Rahima Taugir, Isha Mehta, Muhammad Jamal, Rupalakshmi Vijayan, Rita Offor, Kanayo Nwankwo, Uroosa Arif, Khurram Waheed, Priyanka Kumari, Maulik Lathiya, George Michel, Naushira Pandya, John Halpern, Hassan Nasir & Marcos A. Sanchez-Gonzalez. (2021) Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review. Infection & Chemotherapy 53:1, pages 1.
Crossref
Crossref
Michail S. Lionakis. 2021. Encyclopedia of Mycology. Encyclopedia of Mycology
803
812
.
Xuezhi Yang, Yan Chang & Wei Wei. (2020) Emerging role of targeting macrophages in rheumatoid arthritis: Focus on polarization, metabolism and apoptosis. Cell Proliferation 53:7.
Crossref
Crossref
Andreas Kerschbaumer, Josef S. Smolen, Harald Herkner, Tijen Stefanova, Eva Chwala & Daniel Aletaha. (2020) Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. Nature Medicine 26:6, pages 974-980.
Crossref
Crossref
Kota Nagai, Keisuke Matsubayashi, Kazuki Ide, Kahori Seto, Yohei Kawasaki & Koji Kawakami. (2020) Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Drug Investigation 40:3, pages 197-209.
Crossref
Crossref
John A. Hamilton. (2020) GM-CSF in inflammation. Journal of Experimental Medicine 217:1.
Crossref
Crossref
M. Reza Khorramizadeh & Farshid Saadat. 2020. Animal Biotechnology. Animal Biotechnology
153
171
.
Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Tsutomu Takeuchi, Tadashi Nakamura, Galina Matsievskaia, Barbara Hunt, Thomas Wagner & Bernard Souberbielle. (2019) Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Research & Therapy 21:1.
Crossref
Crossref
Chiara Crotti, Elena Agape, Andrea Becciolini, Martina Biggioggero & Ennio Giulio Favalli. (2019) Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs 79:16, pages 1741-1755.
Crossref
Crossref
S Alivernini, B Tolusso, G Ferraccioli, E Gremese, M Kurowska-Stolarska & I B McInnes. (2018) Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clinical and Experimental Immunology 193:1, pages 13-23.
Crossref
Crossref
Andrew D. Cook & John A. Hamilton. (2018) Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. Therapeutic Advances in Musculoskeletal Disease 10:2, pages 29-38.
Crossref
Crossref
T. W. J. Huizinga, A. Batalov, R. Stoilov, E. Lloyd, T. Wagner, D. Saurigny, B. Souberbielle & E. Esfandiari. (2017) Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Gerd R Burmester, Iain B McInnes, Joel Kremer, Pedro Miranda, Mariusz Korkosz, Jiri Vencovsky, Andrea Rubbert-Roth, Eduardo Mysler, Matthew A Sleeman, Alex Godwood, Dominic Sinibaldi, Xiang Guo, Wendy I White, Bing Wang, Chi-Yuan Wu, Patricia C Ryan, David Close & Michael E Weinblatt. (2017) A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 76:6, pages 1020-1030.
Crossref
Crossref
Helen L Wright, Trevor Cox, Robert J Moots & Steven W Edwards. (2017) Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis. Journal of Leukocyte Biology 101:3, pages 785-795.
Crossref
Crossref
Santos Castañeda & Isidoro González-Álvaro. (2017) Innovations in the therapeutic outlook of rheumatoid arthritis. Reumatología Clínica (English Edition) 13:2, pages 63-65.
Crossref
Crossref
Santos Castañeda & Isidoro González-Álvaro. (2017) Novedades en el panorama terapéutico de la artritis reumatoide. Reumatología Clínica 13:2, pages 63-65.
Crossref
Crossref
John A. Hamilton, Andrew D. Cook & Paul P. Tak. (2016) Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nature Reviews Drug Discovery 16:1, pages 53-70.
Crossref
Crossref
Irina Ushach & Albert Zlotnik. (2016) Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage. Journal of Leukocyte Biology 100:3, pages 481-489.
Crossref
Crossref
J. R. Kalden. (2016) BiologikaBiologics. Zeitschrift für Rheumatologie 75:6, pages 604-610.
Crossref
Crossref
Joachim. R. Kalden. (2016) Emerging Therapies for Rheumatoid Arthritis. Rheumatology and Therapy 3:1, pages 31-42.
Crossref
Crossref
Ian P. Wicks & Andrew W. Roberts. (2015) Targeting GM-CSF in inflammatory diseases. Nature Reviews Rheumatology 12:1, pages 37-48.
Crossref
Crossref
A. Berkant Avci, Eugen Feist & Gerd-R. Burmester. (2015) A Promising Target in Rheumatoid Arthritis Treatment: Granulocyte-Macrophage Colony-Stimulating Factor. Current Treatment Options in Rheumatology 1:4, pages 320-333.
Crossref
Crossref